Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 37154

Reviews
Table of Contents - Year : 2016 | Month : June | Volume : 10 | Issue : 6 | Page : BE01 - BE06

Aptamers in Therapeutics BE01-BE06

Abhishek Parashar

Correspondence
Dr. Abhishek Parashar,
Qr. No-832, Sector-1C, Bokaro Steel City-827001, Jharkhand, India.
E-mail: nanotechabhi2005@gmail.com

Aptamers are single strand DNA or RNA molecules, selected by an iterative process known as Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Due to various advantages of aptamers such as high temperature stability, animal free, cost effective production and its high affinity and selectivity for its target make them attractive alternatives to monoclonal antibody for use in diagnostic and therapeutic purposes. Aptamer has been generated against vesicular endothelial growth factor 165 involved in age related macular degeneracy. Macugen was the first FDA approved aptamer based drug that was commercialized. Later other aptamers were also developed against blood clotting proteins, cancer proteins, antibody E, agents involved in diabetes nephropathy, autoantibodies involved in autoimmune disorders, etc. Aptamers have also been developed against viruses and could work with other antiviral agents in treating infections.